| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/07/2011 | US20110081336 Processing biomass |
| 04/07/2011 | US20110081335 Processing biomass |
| 04/07/2011 | US20110081333 Apparatus and system for treatment and prevention of bags under eyes |
| 04/07/2011 | US20110081332 Treatment of non-alcoholic steatotic hepatitis (nash) |
| 04/07/2011 | US20110081331 Cancer therapy |
| 04/07/2011 | US20110081330 Compositions of fat-soluble active ingredients containing gum ghatti |
| 04/07/2011 | US20110081329 Amino acid compositions |
| 04/07/2011 | US20110081325 Novel treatment of heart diseases |
| 04/07/2011 | US20110081317 Enhancing Gene Transfer |
| 04/07/2011 | US20110081316 Pyrazole inhibitors of phosphatidylinositol 3-kinase |
| 04/07/2011 | US20110081315 Novel macrocyclic inhibitors of hepatitis c virus replication |
| 04/07/2011 | US20110081314 Antiviral phosphinate compounds |
| 04/07/2011 | US20110081312 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 04/07/2011 | US20110081310 Compositions comprising superhydrophilic amphiphilic copolymers and methods of use thereof |
| 04/07/2011 | US20110081309 Compositions comprising a superhydrophilic amphiphilic copolymer and a micellar thickener |
| 04/07/2011 | US20110081297 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles |
| 04/07/2011 | US20110081295 Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration |
| 04/07/2011 | US20110079528 Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
| 04/07/2011 | DE202009018155U1 Zusammensetzung eines Kranbeeren-Derivats und D-Mannose, um Harnwegsinfektionen zu verhindern, zu kontrollieren und zu verbessern In order to prevent urinary tract infections to control composition of a cranberry derivative and D-mannose, and to improve |
| 04/07/2011 | DE102009042459A1 Composition, useful for the treatment and prophylaxis of diseases of the liver, cardiovascular disease, dementia and Alzheimer's disease, comprises colloidal silver, gold and/or platinum and a choline-containing phosphoglyceride |
| 04/07/2011 | DE102005018642B4 Verwendung von Verbindungen zur Hemmung der Glyoxalasen Use of compounds to inhibit the glyoxalases |
| 04/07/2011 | DE10141652B4 Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung The transdermal therapeutic system based on polyacrylate pressure-sensitive adhesives having no functional groups and its use |
| 04/07/2011 | CA2782797A1 Anti inflammatory 2-oxothiazoles and 2-oxooxazoles |
| 04/07/2011 | CA2781276A1 Heteroatom containing substituted fatty acids |
| 04/07/2011 | CA2780695A1 Substituted 5-imino-1,2,4-thiadiazoles that can be used to treat neurodegenerative diseases |
| 04/07/2011 | CA2776779A1 Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| 04/07/2011 | CA2776534A1 Piscine reovirus diagnostic compositions |
| 04/07/2011 | CA2776474A1 Topical tetracycline compositions |
| 04/07/2011 | CA2776464A1 1-desoxy-2-methylene-19-nor-vitamin d analogs and their uses |
| 04/07/2011 | CA2776462A1 (20s,22e)-2-methylene-19-nor-22-ene-1.alpha.,25-dihydroxyvitamin d3 analogs |
| 04/07/2011 | CA2776366A1 Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| 04/07/2011 | CA2776351A1 New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers |
| 04/07/2011 | CA2776327A1 Treatment of disease with proteasome inhibitors |
| 04/07/2011 | CA2776296A1 Therapeutic uses of pharmaceutical compositions |
| 04/07/2011 | CA2776294A1 Pyrazole derivatives which modulate stearoyl-coa desaturase |
| 04/07/2011 | CA2776288A1 Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| 04/07/2011 | CA2776266A1 Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate |
| 04/07/2011 | CA2776217A1 Cosmetic foam |
| 04/07/2011 | CA2776198A1 Cooperative conveyance of basic active principles by amphiphilic acid molecules |
| 04/07/2011 | CA2776164A1 Orally administered corticosteroid compositions |
| 04/07/2011 | CA2776160A1 Smoking cessation with body weight maintenance and nutritional supplement |
| 04/07/2011 | CA2776141A1 Reduced-odor polyol composition and method of producing same |
| 04/07/2011 | CA2775961A1 Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
| 04/07/2011 | CA2775942A1 Pi3k (delta) selective inhibitors |
| 04/07/2011 | CA2775925A1 Salts, solvates and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same |
| 04/07/2011 | CA2775877A1 Methods and compositions for treatment of ocular fibrosis |
| 04/07/2011 | CA2775840A1 Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| 04/07/2011 | CA2775753A1 Novel compounds |
| 04/07/2011 | CA2775670A1 Crosslinked hydrogels and related method of preparation |
| 04/07/2011 | CA2775587A1 Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors |
| 04/07/2011 | CA2775464A1 Indazole analog |
| 04/07/2011 | CA2775418A1 Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors |
| 04/07/2011 | CA2775354A1 Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase |
| 04/07/2011 | CA2775317A1 Topical formulation for diabetic foot ulcers |
| 04/07/2011 | CA2775309A1 Novel phenol derivative |
| 04/07/2011 | CA2775061A1 Methods and compositions for treatment of raynaud's phenomenon |
| 04/07/2011 | CA2774999A1 Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
| 04/07/2011 | CA2774916A1 New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
| 04/07/2011 | CA2774903A1 Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
| 04/07/2011 | CA2774769A1 Novel compounds that are erk inhibitors |
| 04/07/2011 | CA2774754A1 Phosphoramidate derivatives of nucleosides |
| 04/07/2011 | CA2774389A1 Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors |
| 04/07/2011 | CA2774040A1 2, 3-dihydro-1h-inden-2-yl urea derivatives and medical uses thereof |
| 04/07/2011 | CA2774026A1 Compositions comprising an anti-inflammatory blend |
| 04/07/2011 | CA2773618A1 2-pyridone compounds used as inhibitors of neutrophil elastase |
| 04/07/2011 | CA2773483A1 Olopatadine compositions and uses thereof |
| 04/07/2011 | CA2773330A1 Dosage regimen of an s1p receptor modulator |
| 04/07/2011 | CA2772815A1 New benzimidazole derivatives and their use as fxr agonists |
| 04/07/2011 | CA2772797A1 Substituted imidazole derivatives for treatment of alzheimers disease |
| 04/07/2011 | CA2772127A1 Formulations for c-met kinase inhibitors |
| 04/07/2011 | CA2771338A1 Crystalline hydrochloride salts of c-met kinase inhibitors |
| 04/07/2011 | CA2771160A1 Process for preparing biphenyl imidazole compounds |
| 04/06/2011 | EP2306187A1 Cancer eradication program |
| 04/06/2011 | EP2305836A1 Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
| 04/06/2011 | EP2305830A2 Method for evaluation of compound using RSK1 |
| 04/06/2011 | EP2305827A1 Cancer antigen MAGE-A9 and uses thereof |
| 04/06/2011 | EP2305825A1 Method of vitamin production |
| 04/06/2011 | EP2305823A1 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 04/06/2011 | EP2305813A2 Fuctional and hyperfunctional sirna |
| 04/06/2011 | EP2305812A2 Fuctional and hyperfunctional sirna |
| 04/06/2011 | EP2305810A1 miRNAs in the treatment of fibrosis |
| 04/06/2011 | EP2305805A1 Double-stranded polynucleotide |
| 04/06/2011 | EP2305798A2 Detection of mutations in a gene associated with resistance to viral infection, OAS1 |
| 04/06/2011 | EP2305713A1 Human antibodies that bind human TNFalpha |
| 04/06/2011 | EP2305712A1 Human antibodies that bind human TNFalpha |
| 04/06/2011 | EP2305709A1 Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof |
| 04/06/2011 | EP2305694A2 Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| 04/06/2011 | EP2305693A1 Methods and compositions for inhibition of innate immune responses and autoimmunity |
| 04/06/2011 | EP2305689A1 The synthesis of naturally occuring ecteinascidins and related compounds |
| 04/06/2011 | EP2305688A1 Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors |
| 04/06/2011 | EP2305687A1 Quinazoline derivatives |
| 04/06/2011 | EP2305684A1 Poycyloalkylpurines as adenosine receptor antagonists |
| 04/06/2011 | EP2305683A1 Pharmaceutical dosage form comprising oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| 04/06/2011 | EP2305682A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| 04/06/2011 | EP2305680A2 Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol |
| 04/06/2011 | EP2305679A1 Pyrazoline dione derivatives as nadph oxidase inhibitors |
| 04/06/2011 | EP2305678A1 Tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidines as antagonists of serotonin 5-ht6 receptors, methods for the production and use thereof |
| 04/06/2011 | EP2305677A1 Alkyne-aryl-naphthyridin-4(1h)-one derivatives as type IV phosphodiesterase inhibitor |
| 04/06/2011 | EP2305676A1 Synthesis of solifenacin monosuccinate |
| 04/06/2011 | EP2305675A1 Indazoles, Benzothiazoles, and Benzoisothiazoles, and preparation and uses thereof |